The Association of Genetic Polymorphisms With Statin-Induced Myopathy.
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To observe not only the distribution of single nucleotide polymorphism in genes related with pharmacodynamic and pharmacokinetics alteration of statins but also to analyze the correlation between these SNPs and the incidence of statins-induced myopathy.
| Condition | Intervention |
|---|---|
|
Rhabdomyolysis Myopathy |
Genetic: DNA |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Retrospective |
| Official Title: | Association Analysis Between Single Nucleotide Polymorphisms in Statin-Related Genes and The Incidence of Myopathy Among Statin-Treated Patients |
- genotype of specific genes [ Time Frame: one day ]
- single nucleotide polymorphism [ Time Frame: one day ]
Biospecimen Retention: Samples With DNA
whole blood
| Estimated Enrollment: | 150 |
| Study Start Date: | August 2007 |
| Estimated Study Completion Date: | January 2008 |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
1,2
Group 1 for the patients with rhabdomyolysis Group 2 for the control without any myopathy
|
Genetic: DNA
withdraw 5~10mL blood from vein only once during the whole design
|
Detailed Description:
Statins are widely prescribed for the patients with hypercholesterolemia.
Though their efficacy in preventing cardiovascular events has been shown by a large number of clinical trials, myotoxic side effects including myopathy or even more severe,rhabdomyolysis are associated with the use of statins.
Because the incidence of myopathy is various among individuals,polymorphism in genes is supposed to be the main factor.
Due to single nucleotide polymorphism in related genes,level of uptake, clearance and metabolism of statins can be seriously different among individuals resulting in various occurrence of myopathy.
Therefore, analytical study in association between SNP of statins-related genes and the incidence of myopathy is such a critical research which can be applied into clinical fields.
Eligibility| Ages Eligible for Study: | 21 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
National Taiwan University Hospital
Inclusion Criteria:
- Clinical diagnosis of Rhabdomyolysis because of prescription with statins
Exclusion Criteria:
- Carnitine palmityl transferase ll deficiency
- McArdle disease
- Myoadenylate deaminase deficiency
Contacts and Locations| Contact: Yen-Hui Chen, PhD | 886-2-2312-3456 ext 8397 | tcyhchen@ntu.edu.tw |
| Contact: Tzung-Dau Wang, PhD | 886-2-2312-3456 ext 5632 | tdwang@ntu.edu.tw |
| Taiwan | |
| National Taiwan University Hospital | Recruiting |
| Taipei, Taiwan, 100 | |
| Contact: Yen-Hui Chen, PhD 886-2-2312-3456 ext 8397 tcyhchen@ntu.edu.tw | |
| Contact: Tzung-Dau Wang, PhD 886-2-2312-3456 ext 5632 tdwang@ntu.edu.tw | |
| Principal Investigator: Yen-Hui Chen, PhD | |
| Study Director: | Yen-Hui Chen, PhD | National Taiwan Univesity College of Medicine |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00549029 History of Changes |
| Other Study ID Numbers: | 200708077R |
| Study First Received: | October 24, 2007 |
| Last Updated: | October 24, 2007 |
| Health Authority: | Taiwan: Department of Health |
Keywords provided by National Taiwan University Hospital:
|
muscle disorder statins creatine kinase |
Additional relevant MeSH terms:
|
Muscular Diseases Rhabdomyolysis Musculoskeletal Diseases Neuromuscular Diseases Nervous System Diseases Hydroxymethylglutaryl-CoA Reductase Inhibitors Anticholesteremic Agents |
Hypolipidemic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Enzyme Inhibitors Lipid Regulating Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 16, 2013